Webinar: Optical Coherence Tomography in Nonclinical Ocular Drug Development
Sponsored by: Covance
Focused on:
Date: 24th October
Days old: 4487
Time: 3PM London/10AM New York
The application of OCT, an advanced technique for imaging the eye, in nonclinical ocular drug development
The demographic shift to a more elderly population accentuates the need for continued development of therapies for age-related ocular disease. Meeting the demand for new ocular drugs presents unique opportunities and challenges.
Optical Coherence Tomography (OCT), is a noninvasive technique for obtaining high resolution images of ocular tissues. Over the last decade, the application of OCT in ocular drug development, from basic research through clinical trials, has increased, as has recognition of its value by regulatory authorities. During this time OCT technology has and continues to evolve rapidly, with improving image quality, and instrument functionality. As most instruments are designed for clinical use, unfamiliarity with current technical and practical features of OCT use in lab animals may preclude its potential benefit.
This webinar will present features of the use of OCT in nonclinical drug development. The basic functionality of OCT will be discussed and examples from several instrument models and lab animal species will be presented to demonstrate how the technique may be applied in nonclinical studies. Key aspects critical to quality data acquisition, analysis and interpretation will be highlighted and relevant correlations between the nonclinical and clinical settings discussed.
OCT is a specialized and progressing technology. Understanding both capabilities and limitations of OCT will aid the vision scientist in determining how OCT may bring value to nonclinical drug development studies.
Presented by
T. Michael Nork, MD, MS, DABO, FARVO,
Ocular Services On Demand, LLC (OSOD) Consulting Group
Associate Professor of Ophthalmology, School of Medicine and Public Health, University of Wisconsin - Madison
Dr. Nork’s clinical specialty is diseases and surgery of the retina and vitreous. He is also fellowship trained in ophthalmic pathology. Dr. Nork's research focuses on the mechanisms by which various ocular diseases affect the outer retina, especially the rods and cones. Dr. Nork has served as PI for ophthalmology for numerous nonclincial safety and pharmacology studies where he performs surgical and laser procedures and evaluates fundus photographs, angiograms and OCT images. He believes strongly that such translational research is vital for moving research ideas into clinical practice.
Gillian McLellan, BVMS, PhD, DACVO, DECVO, DVO, MRCVS,
Ocular Services On Demand, LLC (OSOD) Consulting Group
Clinical Instructor, Department of Surgical Sciences, School of Veterinary Medicine, Associate Scientist, Department of Ophthalmology & Visual Sciences, School of Medicine & Public Health, University of Wisconsin - Madison
Dr. McLellan, a board-certified veterinary ophthalmologist and scientist, has research interests in comparative glaucomatology including advanced imaging of the retina and optic nerve, as well as the genetics and pathology of glaucoma in animals and humans. Dr. McLellan also has a strong research interest in comparative ophthalmic pathology, in particular diseases of the retina and optic nerve. Dr. McLellan has participated in numerous nonclinical studies for ophthalmology therapies and recently published a comprehensive review of the use of Optical Coherence Tomography in animal subjects.
Brian Christian, PhD, DABT,
Covance Laboratories
Scientific Lead - Ocular Study Services, Nonclinical Safety Assessment
Dr. Christian received his advanced degree in Pharmacology/Toxicology from the University of Wisconsin, Madison and has 25 years of experience as a regulatory toxicologist. He serves as a Senior Study Director and Scientific Lead for Ocular Toxicology at Covance where he has conducted over 350 studies, which over the last 15 years have emphasized development of ocular therapies. He is a Diplomate of the American Board of Toxicology and currently serves on the Executive Committee of the Ocular Toxicology Specialty Section of the Society of Toxicology
Carol Rasmussen, MS,
Ocular Services On Demand, LLC (OSOD) Consulting Group
Associate Research Scientist, Dept Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin - Madison
Carol has conducted basic research in vision science for over 10 years in the Department of Ophthalmology at the University of Wisconsin, Madison. Her research experience has focused on glaucoma and she has particular expertise with OCT imaging of anterior and posterior segments of the eye, as well as electrophysiology and aqueous humor dynamics in a variety of lab animal species. Carol has performed OCT imaging on numerous nonclinical studies and is a coauthor of a recently published comprehensive review on the use of Optical Coherence Tomography in animals.
Key Learning Objectives
- Understand basic principle, functionality of OCT instruments.
- Understand how OCT may be applied to bring value nonclinical studies
- Understand key technical considerations for quality data acquisition
- Understand key aspects of data analysis and interpretation.
Audience
- Clinical Operations
- Laboratory / R&D Scientist
- Pre-clinical Research
- Preclinical Scientists
- Preclinical Consultants
- Consultants for Ocular Drug Development